ADPT: Bull Flag detected on 31 Aug 2026

ADPT is forming a bull flag pattern with strong structural integrity (15/15 structure score). The stock currently trades at $25.19, sandwiched between key support at $23.41 and resistance at $24.96—showing tight consolidation typical of bull flag continuation patterns. Volume has declined to 1.5M shares (72% of 20-day average), which is appropriate for the flag contraction phase. The combination of 15/15 structure, 12/13 breakout, and 11.2/12 volume scores reflects a high-quality setup with 77.69% win probability and an overall 74.2 score.

ADPT reported Q2 2026 revenue of $71.6M (21.5% YoY growth), beating analyst estimates of $67.2M, with gross profit rising 25.7% to $51.4M reflecting stronger product economics. The company raised full-year 2026 MRD revenue guidance, driving a 90-day return of 86.72% and 1-year return of 109.46%. Management announced plans to separate the MRD and Immune Medicine businesses in June 2026, positioning this as a key catalyst that could provide direct exposure to the higher-margin MRD cash flow profile. The company raised $300M in convertible senior notes in mid-June, with combined cash and securities of $371.7M as of quarter-end. The bull flag forms against this backdrop of accelerating revenue growth and business restructuring—both bullish drivers.

A successful breakout above $24.96 resistance would target $26.02 (conservative measure), representing a ~3.3% measured move that aligns with the improved gross margins and MRD adoption momentum. The pattern suggests volume should expand on breakout confirmation above resistance, with invalidation occurring below $23.41 support where the underlying trend would be questioned. The 77.69% win probability reflects strong historical patterns in this configuration, supported by accelerating adoption of MRD across clinical testing and drug development. Technical indicators show RSI at 55.14 (neutral, not overbought), providing room for upside without overextension.

The most material risk is a massive divergence between growth narrative and financial reality. Despite 21.5% revenue growth, ADPT posted an operating loss of $15.8M and net loss of $39.8M in Q2 2026. Investors must believe MRD can evolve into a self-funding franchise while the broader company manages continued losses and cash burn, with the latest results showing this tension remains front-and-center. Cash runway of $169.9M is adequate but insider selling has dominated—92 insider transactions in 6 months with all 92 being sales and zero purchases, signaling cautious management sentiment. The planned business separation adds execution risk. ATR volatility at 4.33% and beta of 1.09 indicate moderate but elevated sensitivity to sector rotations away from unprofitable biotech.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.